1789 TT

ScinoPharm Investor Conference

— 2023 03 09

ScinoPharm Taiwan

Disclaimer

This material has been prepared by ScinoPharm Taiwan, Ltd. (“ScinoPharm”).

Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. ScinoPharm is under no obligation to update or keep current the information contained herein. The **information contained** in this presentation **is** ScinoPharm’s **confidential** information.

Any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

No representation or warranty, express or implied, is or **will be made** in or in relation to, and no responsibility or liability is or will be accepted by the Company **as to**, the **accuracy or completeness** of this material and any liability therefore is hereby expressly disclaimed.

Statements made in this material include forward-looking statements, which include, without limitation, statements about the issues, plans and expectations of ScinoPharm. Without limiting the foregoing, statements including the words “believes”, “anticipates”, “plans”, “expects” and similar expressions are also forward-looking statements. Forward-looking statements reflect, among other things, management’s plans and objectives for future operations, current views with respect to future events and future economic performances and projections of various financial items. **These forward-looking statements involve known and unknown risks**, uncertainties and other factors **which may cause actual results to differ materially from those implied** by such forward-looking statements.

Agenda

01 Overview of Business Operations

02 Business Update

03 2023 Product Approval Plan

04 Financial Performance



Overview of Business Operations

I. Implement Development Blueprint and Realize Vertical Integration Gradually

- Examined the company's advantages and responded to changes in the environment. Implemented its development blueprint gradually and integrated from APIs to drug product
- Drove the production and marketing of core APIs and strengthened the deployment of APIs and drug product. Renovated plants and reshaped work allocation to support essential products and realized disciplined internal operations and strengthened operational efficiency
- The consolidated revenue in 2022 was 109.43 mil. USD, +10.9% yoy, or 3,264 mil. NTD, +18.2% yoy; NPAT was 353 mil. NTD, up 45.1% yoy, with NPAT margin of 10.8%
- 2023 will be the continuously investing year

II. Pursue Growth by Focusing on Strengths

- Developed integration skills in manufacturing process development, commercial mass production, and high-standard quality control continuously
- Strengthened hardware facilities and workforce to expand capacity and efficiency of R&D and manufacturing
- In-house API Products
  - Built up the company's ability to supply core API through planned deployment
- CDMO Business
  - Focused on small molecules and peptides to increase the practice of businesses and fulfill the diverse needs of customers

III. Commercial Production Begins in Drug Product Business

- In-house prefilled-syringe, liquid solution and lyophilized powder injectable production lines have performed the US FDA Pre-Approval Inspection (PAI) in Mar. and Oct. 2022, and passed respectively. The company achieved an outstanding zero 483 in the second inspection
- Customized drug development & manufacturing stepped into commercial mass production and accumulated capabilities of injectable product manufacturing continuously. In-house prefilled-syringe, liquid solution, and lyophilized powder injectable products are going through a review process of ANDA submissions.
- Focused on strengths of complex injectable and peptide products for expand in business
- Utilized the benefits of API production and supply for seeking new product development



Business Updates

2022 Approved Products

Type	Product	Region	Indication	Brand Marketer
Generic API	Irinotecan HCl	CN ✓	Colorectal cancer	Pfizer
Generic API	Anastrozole	CN ✓	Breast cancer	ANI Pharmaceuticals
Generic API	Azilsartan	CN ✓	Hypertension	Arbor Pharmaceuticals
Generic API	Regadenoson	US ✓	MPI	Astellas
Generic API	Topiramate	EU ✓	Weight management	Vivus
CDMO API	Camcevi	EU ✓	Cancer	Foresee
CDMO API	Ganaxolone	US ✓	Genetic epilepsy	Marinus
Generic Drug	Pemetrexed 2Na	US ✓ EU ✓	Non-small cell lung cancer	Eli Lilly
Generic Drug	Bortezomib	EU ✓ US ✓	Multiple myeloma	Takeda

Optimize Generic API Portfolio

Generic API Portfolio



Expand CDMO Business

CDMO Business Status



As of 2023/01/31

Advancing to Injectables

In-House Drug Product Submission Status



Advancing to Injectables

Collaborative Projects for Drug Product

In-house Prefilled - syringe product

Signed marketing agreement with partner

Collaboration on 505(b)(2) for non-small cell lung cancer

Launched in US in Feb., 2022 by customer

Collaboration on ANDA for non-small cell lung cancer

Approved by US FDA in Aug., 2022 and by EMA in Dec., 2022

Collaboration on ANDA for multiple myeloma

Approved by US FDA in May, 2022

China Market

- 4 CFDI on-site inspections completed in Changshu site to facilitate China market growth

	Product	Approval	Indication	Market
2020.09	Sodium Phenylbutyrate*	2021.05	Urea cycle disorders	Orphan disease medicine
2021.02	Donafenib	2021.06	Advanced liver cancer Thyroid cancer	2023 sales projected by research report : c. RMB 600 million
2021.06	Bimatoprost	2023.02	Glaucoma	Prostaglandin drug products c. RMB 1 billion
2022.11	Azilsartan	2022.09	Hypertension	c. RMB 100 million

* Customer's clinical trial for new indication in progress

- Changshu site expects to conduct more inspections in 2023



2023 Product Approval Plan

2023 Product Approval Plan

Type	Product	Region	Indication	Brand Marketer
Generic API	Bimatoprost	CN(✓)	Glaucoma	Allergan
Generic API	Cladribine	CN	Multiple sclerosis	Merck
Generic API	Galantamine HBr	CN	Alzheimer's disease	Janssen
Generic API	Azacitidine	EU	Myelodysplastic syndromes	Celgene
CDMO API	Ganaxolone	EU	Genetic epilepsy	Marinus
CDMO API	Eflornithine	US/EU	FAP	Post-marketing disclosure
CDMO API	Eflornithine	US/EU	Pediatric neuroblastoma	Post-marketing disclosure
Intermediate for CDMO API	Sotagliflozin	US	Heart failure	Lexicon

✓：Approved



Financial Performance

Consolidated Income Statement

NTD Million except for EPS	2022		YoY	2021	
Revenue	3,264	100%	18%	2,762	100%
Gross Profit	1,251	38%	-2%	1,280	46%
Operating Expenses	(845)	(26)	-15%	(992)	(36)
Operating Profit	405	12%	40%	289	10%
Net Profit before Tax	438	13%	45%	302	11%
Net Profit after Tax	353	11%	45%	243	9%
EPS (NTD)	0.45	-	45%	0.31	-

Sales Distribution – By Business





Unit: USD/M

	Generic API	CDMO	Drug Product
FY 2022 Sales	71.7	23.3	14.4
YoY in US$	-0.3%	58.5%	19.6%
YoY in NT$	6.0%	69.6%	28.2%

Sales Distribution – By Indication





Unit: USD/M

	Oncology	CNS	Others
FY 2022 Sales	71.9	23.5	14.0
YoY	5.1%	2.4%	90.8%

Sales Distribution – By Region





Unit: USD/M

	US & Canada	EU	Japan	India	China	Others
FY 2022 Sales	23.7	19.8	20.9	19.3	11.0	14.7
YoY	-14.3%	-4.6%	-20.0%	135.0%	64.1%	60.0%

Consolidated Balance Sheet

NTD Million	2022/12/31		2021/12/31	
Cash and Cash Equivalents	4,295	36%	4,081	35%
Accounts Receivable	635	5%	360	3%
Inventories	1,189	10%	1,345	12%
Property, Plant & Equipment	3,843	32%	4,033	35%
Other Current/Non-Current Assets	1,949	17%	1,872	15%
Total Assets	**11,911**	**100%**	**11,691**	**100%**
Financial Debt	78	1%	0	0%
Other Current Liabilities	725	6%	556	5%
Other Non-Current Liabilities	658	5%	624	5%
Total Liabilities	**1,461**	**12%**	**1,180**	**10%**
Total Shareholders' Equities	**10,450**	**88%**	**10,511**	**90%**

Consolidated Cash Flow Statement

NTD million	2022	2021	Dif.
From Operating Activities	**774**	**510**	**264**
Depreciation & Amortization	439	382	57
From Investing Activities	**(253)**	**(70)**	**(183)**
Capital Expenditure	(250)	(321)	71
From Financing Activities	**(315)**	**(413)**	**98**
Effect of foreign exchange rate changes	**8**	**(1)**	**9**
Net Change in Cash	**214**	**26**	**188**
Beginning Balance	**4,081**	**4,055**	**26**
Ending Balance	**4,295**	**4,081**	**214**



Q & A

Appendix
Company Overview

ScinoPharm at a Glance

- Est. 1997 in Taiwan with R&D/CGMP plants in Tainan and Changshu, China plus marketing forces in Tainan, Shanghai and Tokyo
- Specializes in providing R&D and CGMP manufacturing of APIs (cytotoxic/steroid) and injectable drug products
- 74 generic APIs in portfolio with 37 referred and approved ANDAs/NDAs*
  - 899 active DMFs worldwide with 67 US DMFs*
- 150+ contract projects with 11 approved/launched (9 NCEs) and 6 in phase 3 for NDA/MAA filing within 1-3 years*
- API plant certified by key international regulators - US FDA, EMA, EDQM, Australian TGA, Japanese PMDA, Korea KFDA, Mexico COFEPRIS and German Authority
- Injectable plant certified by US FDA and TFDA

*As of 2023/01/31

Brand Quality with Asian Advantages

www.scinopharm.com

1789 TT